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1. Introduction 
IgA Nephropathy (IGAN) is also called mesangial IgA glomerulonephritis and was first 
described by Jean Berger, a French general pathologist, in 1968 in the journal d’Urologie-
Néphrologie [1, 2]. Many reviews have been written on the subject [3, 4, 5]. 
2. Definition [3, 4, 5] 
The definition is histopathologic with the characteristical deposition of the 
immunoglobulin A in the renal mesangium: these deposits are predominant (or 
codominant with other immunoglobulins, IgG and/or IgM), granular, coarse (with the “en 
mottes” aspect), generalized in the glomerulus and diffuse to all glomeruli. These deposits 
are evidenced usually by the technique of direct immunofluorescence on a semi-quantitative 
scale: traces (+/-), 1+, 2+, and ≥ 3+. There is a general agreement to accept at least 1+ IgA 
deposits for the definition. 
By contrast, the lesions observed by light microscopy are often segmental and focal. The main 
lesions concern the mesangium with increased matrix and hypercellularity with in addition 
endocapillary proliferation. The most severe lesions are represented by obsolescent glomeruli 
(“pains à cacheter”), focal and segmental glomerulosclerosis (FSGS) with capsular adhesions, 
and extracapillary proliferation with the formation of cellular/hyalinized crescents. 
3. The IgA nephritides [3, 4, 5] 
The deposition of mesangial IgA has been observed in different types of glomerulonephritis 
leading to the classification of Primary IgA nephropathy (Berger’s disease) versus the 
Secondary IgA nephropathies: associated to Schönlein-Henoch Purpura, to patent 
Alcoholic Liver Cirrhosis, to Systemic lupus Erythematosus, or to Ankylosing 
Spondylarthritis. Primary disease represents at least 80 % of the cases.  
4. Epidemiology [3, 4, 5] 
Primary IGAN is worldwide the most frequent glomerulonephritis; it accounts for about a 
quarter of the percutaneous renal biopsies performed on native kidneys. In France, the 
incidence is about 30 new cases per million inhabitants (pmp) and its prevalence is closed 
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to 1000 pmp according to the disease duration from onset to dialysis or to last follow-up 
(from few months to more than 5O years). All these numbers are of course dependent of the 
“politic” of renal biopsy: liberal indication or restricted to the most severe cases with already 
proteinuria over 1g/day or already some degree of renal insufficiency (Glomerular 
Filtration Rate <60 ml/mn/1.73 m² body surface area). 
The disease is more frequent in men than in women, about 70% males, in most continents 
except in Asia. Age at onset ranges from 5 years to 75 with a peak frequency in adolescents 
and young adults. 
 
 
Fig. 1. HistoPathology of IgA Nephropathy: 
(a) Light microscopy showing one glomerulus with segmental  increased in mesangial 
matrix and mild hypercellularity. 
(b) Immunofluorescent microscopy showing diffuse IgA deposits in all glomeruli. 
(c) Immunofluorescent microscopy showing generalized mesangial IgA deposits within all 
the glomerulus surface/volume. 
5. Mode of onset/initial presentation [3, 4, 5] 
The onset of the disease can be acute/subacute in about 30 to 35 % of the patients with the 
classical intra-infectious gross haematuria: at time of an infectious episode of various 
origin (pharyngitis, bronchitis, or even intestinal or urinary infection), the patient is 
urinating blood  with colored urine, more brown than red with a color of coffee or coca-
cola; this is a total haematuria (sometimes with loin pain) which lasts from few hours to 
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few days; there is no clot and the characteristics of this gross haematuria is nephrological 
with the presence on urine cytology of typical red blood cell casts. After such an episode, 
the patient is usually presenting microscopic haematuria or could be in total remission 
until the next episode. 
The discovery can be chance proteinuria or chance microscopic haematuria at time of 
systemic  urine control for medical check-up at school, at different institutions or at work; 
the time of onset is therefore imprecise and we should refer to the last negative control if 
any. 
The disease can be diagnosed later on with arterial hypertension (HT) and/or oedema 
and/or chronic kidney disease stage 3 or up (CKD-3+). 
6. Progression of the disease [6-12] 
Overall, IGAN is a progressive disease both clinically and pathologically. The clinical 
progression starts with urine abnormalities, followed by occurrence of HT, sometimes 
oedema related to massive proteinuria or nephrotic syndrome, and later on occurrence of 
CKD-3 through CKD-5 and ultimately renal death necessitating chronic dialysis. The 
progression is also pathological and this was demonstrated by repeated renal biopsies 5 
years later [6, 13]: it was shown that the global optical score (GOS) progressed in the 
majority of the patients with increased glomerular but also vascular and tubular/interstitial 
indices. 
We are taking as example our prospective cohort of primary IGAN patients [12] whose 
diagnostic biopsy was performed between January 1st 1990 and December 31st 1999 at our 
institution with loco-regional patients coming from the Saint-Etienne area, the IGAN-STET-
CO. This cohort is composed of 332 patients (237 men, 71.4 %) with a mean age of 35.9 at 
onset, 41.4 at diagnosis and 48.8 years at dialysis/death or at last follow-up visit. The total 
exposure time was about 13 years. Overall, 32 patients needed dialysis, 13 died before 
reaching dialysis, and 45 (13.6 %) reached the primary composite outcome while 99 (29.8 %) 
presented the secondary outcome (CKD-3+). 
7. Predictive risk factors and the absolute renal risk of dialysis/death: A new 
concept [12] 
One very important goal was to sort out the major and independent risk factors (RF), 
present at diagnosis, able to predict accurately the ultimate final prognosis (dialysis or death 
as primary end-point). From the literature, we already know that the amount of proteinuria 
(g per day), the occurrence/presence of HT, and the severity of renal lesions on the initial 
biopsy were associated with progression [6-11]. Many other risk factors were also described 
such as gender, overweight/obesity [14], metabolic syndrome, age at onset [15], 
hypertriglyceridemia/hyperuricemia [16], and also different immunogenetic markers (HLA 
antigens, different cytokines polymorphisms [17, 18],…) but they were not consistent or 
controversial in different published cohorts. We recently confirmed [12] that these 3 major 
risk factors were sufficient to cover the whole prediction in our cohort. These risk factors 
were simplified, dichotomized for easier use and shown to be independent predictors in a 
multivariate model of Cox regression: - the most important is the presence of HT (Yes or 
No) defined according to WHO (≥ 140/90); - the next is the presence of Proteinuria ≥ 1g/d 
(Yes or No); and - the last is the scoring of the renal lesions; we have used our own global 
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optical score (GOS) developed 20 years ago and integrating all elementary lesions 
(glomerular from 0 to 6, vascular from 0 to 5, tubular from 0 to 4, and interstitial from 0 to 5) 
with a GOS up to 20. We set up by ROC analysis that the best cut-off for predicting dialysis 
was the presence of GOS ≥ 8 (Yes or No). These 3 RF turned out to have a similar weight in 
the prediction of dialysis/death by the different accuracy parameters and also by the Cox 
regression (ǃ/SE ratio of the same magnitude). 
In analogy to the absolute cardio-vascular risk (ACVR) of death or major CV events at 10 
years [19, 20], we proposed the Absolute Renal Risk of Dialysis/Death; this ARR is 
calculated at diagnosis and is very simply the number of these RF present: 0, 1, 2 or 3. By 
Kaplan-Meier survival curves, we could calculate the cumulative rate of primary event at 10 
and 20 years after onset (time zero); it was respectively 2 and 4 % for ARR=0; 2 and 9 % for 
ARR=1; 7 and 18 % for ARR=2; and 29 and 64% for ARR=3. 
In addition, this ARR integrates gender (less RF for women), age at diagnosis (more RF for 
older patients), and also body mass index (more RF in overweight/obese patients). We 
could also use it as prospective with time zero set-up at diagnosis and not at onset; the 
cumulative incidence of dialysis/death 10 years after diagnosis is 4% for ARR=0, 8% for 
ARR=1, 18% for ARR=2, and 68% for ARR=3. It is remarkable to underline the similarity of 
the values obtained 20 y after onset and 10y after diagnosis. 
Distribution of these Risk Factors at time of Diagnosis and at last follow-up (LFU): HT 
was present in 120 patients (36.1%) at diagnosis and in 164 (49.4%) at LFU; Proteinuria 
≥1g/d was present in 100 patients (30.1%) at diagnosis and in only 61 (18.4%) at LFU; and 
GOS ≥ 8 was present in 120 patients (36.1%) at time of diagnosis. The distribution of the 
ARR was as follows at time of diagnosis: 151 patients (45.5%) with ARR=0, 69 (20.8%) with 
ARR=1, 65 (19.6%) with ARR=2, and 47 patients (14.1%) with ARR=3. 
It should be stressed that this cohort is an adequately treated cohort with all RF targeted as 
soon as they were identified: perfect control of blood pressure (target <130/80) with all 
antihypertensive agents; persistent reduction of proteinuria with ACEI and ARBs; and 
prednisolone for severe renal lesions. 
8. Pathological classification of IgA nephropathy 
We have developed our own classification in 1990 [6, 13] with the Global Optical Score 
already described. During the past decades, the classifications of Haas [21] or Hass modified 
by Lee [22] were frequently used. The international Oxford classification was published in 
2009 [23, 24] and retained only 4 parameters with significant clinical prediction: - mesangial 
hypercellularity (M score= 0 or 1); - endocapillary hypercellurarity (E score= 0 or 1);  
- segmental glomerulosclerosis (S score= 0 or 1); and - tubular atrophy/interstitial fibrosis  
(T score= 0 or 1 or 2). Overall, the MEST score ranges from 0 to 5. One limitation is that 
patients were only included if proteinuria was ≥ 1g/d in adults and there was no patients  
with ARR=0 who are in fact the majority of the patients; in addition patients with 
extracapillary GN (≥ 50% crescents) were also excluded; the two tails of the IGAN cohorts 
were therefore lacking! 
9. Principles of treatment in IGAN 
The treatment should in fact target all major risk factors when present: hypertension, 
proteinuria, and severe renal lesions. 
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The permanent control of HT is a major step; the goal is to lower BP ≤ 130/80. Sodium 
chloride restriction is recommended with 24 h urinary sodium below 100 mmol/d 
corresponding to a maximum of 6 g daily sodium chloride. All antihypertensive agents can 
be used: diuretics, beta blockers, calcium blockers, central-acting, ACE inhibitors, 
angiotensin-2-receptor blockers (ARBs), and more recently renin inhibitors. However two 
classes have demonstrated a better protection and should be used alone or in association: 
ACEI and ARBs [25, 26]. In our prospective cohort [12], we have demonstrated that survival 
without dialysis/death improved in patients with adequately controlled BP on long term 
[27]. 
The significant reduction of proteinuria is another major step [28]; the reduction can be 
obtained with the use of ACEI and ARBs which have a significant antiproteinuric effect. It is 
recommended to start with either one of these drugs, to titrate the dose to the effect, and to 
use the association in case of resistant proteinuria; the goal is to bring proteinuria ≤ 1g/d  or 
ideally < 0.30 g/d. We have also demonstrated [12] that the permanent reduction of 
proteinuria is associated with a better survival on long-term. 
The treatment of severe renal lesions on the biopsy; this could be achieved by Prednisone 
or Prednisolone treatment [29-31] which should be in theory able to reduce hypercellularity 
and cellular infiltration within the glomeruli; however in the trial, there was no repeated 
biopsies at the end of the steroid therapy. For the most severe cases with extracapillary GN 
(>50 % crescents), the association of high dose steroids and immunosuppressive agents as 
already proposed might be a good option. 
The use of Fish Oil was limited with controversial results [32, 33]. 
We are still in the need of large randomized controlled trials with a long duration (5 years 
seems optimal) to draw definite conclusions on the treatment of IGAN. 
10. Pathogenesis and patho-physiology of primary IgA nephropathy 
Very significant progress has been made during the last decades. The key protein in this 
disease is the immunoglobulin A and more precisely the subgroup 1; in fact IgA1 is 
deposited in the mesangium but not IgA2 [34]. The major difference between IgA1 and IgA2 
is the presence of an hinge region in IgA1 composed of 23 aminoacids with usually five 
sugar side chains linked to threonin or serin. There is now a consensus [35-39] about the fact 
that the main difference between IgA1 in Controls and in IGAN patients is the hypo-
galactosylation of these  glycosylated side chains. The normal complete sugar chain is  
O-linked to threonine or serin and composed of one molecule of N-acetyl galactosamine 
(GalNac) and one molecule of Galactose; in addition a molecule of sialic acid can be  
bound in terminal to Galactose or in lateral to GalNac. In IGAN, more side chains are 
truncated with loss of terminal Galactose with its terminal sialic acid and is referred to the 
Galactose-deficient IgA1 (deGal-IgA1). This deGal-IgA1 represents the specific autoantigen 
in this disease and is present in the serum, within the circulating immune complexes and in 
the mesangial deposits [40]. This loss in terminal galactose is associated with a down-
regulation of the gene controlling the linkage of galactose to GalNac, C1GALT1 [41] and the 
description of specific polymorphism [42] raising the possibility of genetic predisposition 
[43]. 
The loss of terminal galactose unusually exposed the GalNac molecules, which become 
antigenic with elicitation of a specific antibody response [44, 45]: IgG and/or IgA anti O-
GalNac, the specific auto-antibodies. It is now possible to measure the amount of circulating 
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autoantigen and autoantibodies in patients sera and to discriminate between Controls and 
IGAN patients [46, 47]. 
The mesangial deposition of deGal-IgA1 is dependent on physical characteristics of this 
molecule (more sticky) and the presence of transferrin receptor (CD71) which is able to bind 
IgA1 variants [48]. After binding, the deGal-IgA1 and the deposited immune complexes are 
able to activate the different mediators of inflammation both cellular [49] and in fluid phase.  
There is also the CD89 system [50] that we personally consider as an amplification loop. This 
is a specific receptor for IgA1 variants, FcǂRI, present on circulating monocytes but not in 
the mesangium; this receptor is able to bind immune complexes with further amplification 
and longer persistence in the circulation, and may play an additional pathogenic role. 
11. Renal transplantation in patients with biopsy-proven IGAN on native 
kidneys 
In cases which progressed to dialysis, renal transplantation should be a strong option and 
overall the results are similar to the other recipients matched for age and gender. However, 
there are two specific situations which have strong pathogenic implication.  
First, a silent IgA nephropathy can be present on grafted kidney from apparently normal 
donors leading to the discovery of mesangial IgA deposits on graft biopsies performed early 
after transplantation; it was demonstrated in few cases that these deposits can regress and 
disappear demonstrating a contrario that the disease has a systemic (blood) transmission. 
Second, the original disease may reappear (recurrence) on the normal grafted kidney after 
few years and despite immunosuppression [51-59]. The cumulative incidence of clinic-
pathological recurrence is high reaching 35 % or more at 10 years post-transplant [56] and 
may lead to graft losses in up to 17 % at 10 y [57]. The factors associated to recurrence are 
not well understood: living donors, better HLA matching, short duration of the original 
disease, etc. There is yet no specific treatment for the recurrent disease; however in a 
retrospective study [56] we demonstrated that induction treatment with ATG seems able to 
reduce the incidence of recurrence in comparison to no induction or to  induction with 
Basiliximab. A prospective randomized controlled trial comparing rabbit ATG to 
Basiliximab has already started, the PIRAT study: Prevention in IgA nephropathy recipients 
of full Recurrence After renal Transplantation according to induction immunosuppressive 
therapy: ATG versus Basiliximab. It seems now mandatory to carefully measure the serum 
levels of the auto-antigen and the auto-antibodies at time of grafting to check for any 
predicting value of these parameters for recurrence. 
12. Conclusions 
IgA nephropathy is a frequent disease whose individual prognosis can be totally different: 
no significant progression for 50 years versus progression to dialysis in few months or years. 
The clinical challenge is to accurately predict the long term individual prognosis at time of 
diagnosis (at time of the renal biopsy which is still mandatory for this purpose). We have 
made significant progress with our new concept: the Absolute Renal Risk of 
Dialysis/Death (ARR); it takes in account the presence or not of three independent, 
simplified and dichotomous risk factors: - arterial hypertension; - proteinuria ≥1g/d; and 
severe histopathological lesions appreciated by the Global Optical Score ≥ 8 (range from 0 
to 20). The cumulative incidence rate of primary event (dialysis or death) at 10 years post-
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diagnosis, is 4 % for ARR=0; 8 % for ARR=1; 18 % for ARR=2; and 68 % for ARR=3 in our 
prospective cohort adequately treated/managed on long term. 
The pathogenesis of the disease has also made significant progress: it is an auto-immune 
disease with a known auto-antigen, the Galactose-deficient IgA1, which can elicit a specific 
auto-antibody response, IgG and IgA anti-O-GalNac. There is formation of specific immune 
complexes which are circulating and then deposited in the mesangium with creation of the 
disease. These recent findings will have significant future applications in the diagnosis and 
in the treatment. 
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